Navigation Links
Sanofi-aventis U.S. to Acquire Oral Chronic Lymphocytic Leukemia Treatment
Date:5/11/2009

BRIDGEWATER, N.J., May 11 /PRNewswire-FirstCall/ -- Sanofi-aventis U.S. announced today that it has acquired from biotechnology company Antisoma plc the U.S. commercial rights to Oforta(TM) (fludarabine phosphate film-coated tablets), an oral B-cell chronic lymphocytic leukemia (CLL) drug. Oforta is currently approved in the United States for use as a second-line therapy to treat adults with B-cell CLL.

"We are extremely pleased to add Oforta to our existing oncology portfolio, and believe it represents an exciting opportunity for sanofi-aventis U.S.," said John Harrington, Vice President and Head of the Oncology Business Unit at sanofi-aventis U.S. "Sanofi-aventis is a company committed to identifying and exploring new treatment options for patients facing serious diseases, such as CLL. This agreement further supports our efforts to help patients and complements our strong heritage of providing therapies to treat cancer."

Antisoma currently licenses certain rights and purchases Oforta from Bayer Schering Pharma AG. As part of this transaction, sanofi-aventis U.S. will acquire these agreements.

Oforta is a nucleoside analogue designed to prevent cancer cells from dividing by inhibiting DNA synthesis. Oforta was granted accelerated review and later received approval from the U.S. Food and Drug Administration (FDA) in December 2008 to treat adult patients with B-cell CLL whose disease has not responded to, or has progressed during or after treatment with at least one standard alkylating-agent containing regimen. Oforta is an orally administered tablet formulation of fludarabine phosphate.

About Oforta

Oforta is indicated as a single agent for the treatment of adult patients with B-cell CLL whose disease has not responded to, or has progressed during or after treatment with at least one standard alkylating-agent containing regimen. Studies demonstrating clinical b
'/>"/>

SOURCE sanofi-aventis
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. BioWa Announces License of POTELLIGENT(R) Technology to sanofi-aventis
2. AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia
3. RainDance Technologies Signs a Collaboration Agreement with sanofi-aventis and Louis Pasteur University to Launch dScreen Consortium within ALSACE BIOVALLEY cluster
4. ThalesNano Inc. and sanofi-aventis R&D Collaborate on Continuous Process Chemistry in Order to Dramatically Reduce Drug Realization Time
5. Sanofi-aventis SoloSTAR(R) Insulin Pen for Lantus and Apidra Receives the Prestigious GOOD DESIGN Award
6. Shareholder Class Action Filed Against Sanofi-Aventis by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
7. Sanofi-aventis Announces Settlement of Average Wholesale Price Civil Suits With the U.S. Department of Justice Relating to Anzemet(R)
8. Cord Blood America to Acquire or Build Its Own Stem Cell Laboratory
9. ChemDiv Group Acquires Prudentas Through ChemRar High Tech Center
10. Sigma-Aldrich Acquires Sigal Ltda and Expands Operations in Chile
11. Leading Middle East Cancer Hospital Acquires Advanced Radiotherapy Capability from Varian Medical Systems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... The Conference Forum announced ... Advance Clinical Trials conference taking place on September 19-20 ... , Disruptive thinkers from Novartis, Pfizer, Eli Lilly, ... approaches to reduce expensive infrastructure, engage patients and generate ... be big, or novel, or it must change the ...
(Date:5/22/2013)... 2013  Empire Genomics announced today it has ... novel genomic biomarker from Cornell University for use ... help in diagnosing and determining treatment for patients ... Neuroendocrine prostate cancer (NEPC) is a lethal variant ... novo, but more commonly arises after hormonal therapy ...
(Date:5/22/2013)... CANTON, Mass. and NEW ORLEANS ... commercial leader in the field of regenerative medicine, presented ... expert economists from Analysis Group (a leading health economics ... that diabetic foot ulcers (DFU) and venous leg ulcers ... The results of this research, which reveal annual ...
(Date:5/22/2013)... -- Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Company ... Microcap Conference, May 30, in New York, NY ... , CPA, Chief Financial Officer of Cleveland BioLabs, will present ... 1:30 p.m. Eastern Time.  A live and archived webcast of ... of the Cleveland BioLabs website at www.cbiolabs.com . ...
Breaking Biology Technology:Disruptive Innovation Hits Clinical Trials, Dedicated Event Launches 2Empire Genomics Licenses Novel DNA Biomarker for Use in Diagnosing and Creating a Companion Diagnostic Test for Neuroendocrine Prostate Cancer 2Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers 2Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers 3Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers 4Cleveland BioLabs to Present at Second Annual Marcum LLP Microcap Conference 2
... 4, 2011 Tengion, Inc. (Nasdaq: TNGN ), ... a conference call and live audio webcast on Thursday, May ... update and discuss its first quarter 2011 financial results.   ... (domestic) or 1-617-597-5328 (international) and reference access code 64874944. ...
... Researchers at the Institute for Genome Sciences at the ... the FBI, the U.S. Army Medical Research Institute of ... first scientific paper based on their investigation into the ... its use of genomics and microbiology in a criminal ...
... to develop a new drug that will regenerate a ... a person is exposed to deadly chemical warfare agents. ... Ohio State University (OSU), is leveraging Ohio Supercomputer Center ... to lethal chemicals called organophosphorus (OP) nerve agents. ...
Cached Biology Technology:Tengion to Host Conference Call to Provide a Business Update and Report First Quarter 2011 Financial Results on May 12, 2011 2University of Maryland School of Medicine publishes scientific paper on 2001 anthrax attacks 2University of Maryland School of Medicine publishes scientific paper on 2001 anthrax attacks 3University of Maryland School of Medicine publishes scientific paper on 2001 anthrax attacks 4OSU chemist developing solution to nerve agent exposure 2
(Date:5/23/2013)... are billions of animal and plant specimens from birds, ... stacked, stored and preserved in jars and collection drawers. ... to understanding how the Earth,s biodiversity is changing in ... only the information were easily accessible. , A new ... a team from the University of Colorado Boulder, is ...
(Date:5/23/2013)... MADISON, Wis. In an age when microbial pathogens ... to tamp down infection, a team of Wisconsin scientists ... of curbing the bacteria that cause staph infections. , ... Chemical Society , a group led by University of ... interfere with the "quorum sensing" behavior of Staphylococcus ...
(Date:5/22/2013)... durability in fuel cell powered buses, including a ... between electrode degradation processes and bus membrane durability. ... electrode degradation stressors in the operating cycle of ... findings of the study, led by SFU graduate ... long-term study at Burnaby-based Ballard Power Systems and ...
Breaking Biology News(10 mins):CU-Boulder helps tap crowds to digitize museum records of bugs and plants 2CU-Boulder helps tap crowds to digitize museum records of bugs and plants 3CU-Boulder helps tap crowds to digitize museum records of bugs and plants 4University of Wisconsin chemists find new compounds to curb staph infection 2Tests lead to doubling of fuel cell life 2
... Accurate duplication of genetic material and the faithful ... initiation of DNA replication is linked both to cell ... other "eukaryotes," the assembly of a multi-protein complex called ... initiation of DNA replication. As the name implies, origin ...
... ,PROVIDENCE, R.I. [Brown University] Seemingly healthy adults, if ... physiological consequences decades later. In research published online last ... led by psychiatrists at Brown University and Butler Hospital ... kids appear to have an elevated inflammatory response to ...
... Mont. -- Invasive plants make life tougher for farmers and ... Missouri River Basin, so why not turn the plants into ... Russian olive and saltcedar alone could supply biomass far into ... Converting invasive plants to fuel is an intriguing idea ...
Cached Biology News:Novel protein critical for cellular proliferation discovered 2Childhood adversity may lead to unhealthy stress response in adult life 2Childhood adversity may lead to unhealthy stress response in adult life 3Montana State, partners in 6 states consider converting invasive plants to fuel 2Montana State, partners in 6 states consider converting invasive plants to fuel 3Montana State, partners in 6 states consider converting invasive plants to fuel 4
Formulation: 10mM PBS/500 mM NaCl, 0.09% NaN3, pH 7.2...
p27 rabbit polyclonal antibody...
Rabbit polyclonal to Shigella (HRP) ( Abpromise for all tested applications)....
Rabbit polyclonal to Aortic Elastin ( Abpromise for all tested applications). entrezGeneID: 2006 SwissProtID: P15502...
Biology Products: